[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 518 pages | ID: C258B46980CEEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 29, 12, 1, 76, 42 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 8 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cystic Fibrosis - Overview
Cystic Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cystic Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cystic Fibrosis - Companies Involved in Therapeutics Development
Cystic Fibrosis - Drug Profiles
(ammonium chloride + citric acid + sodium citrate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(elexacaftor + ivacaftor + tezacaftor) + ivacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
(ethylenediaminetetraacetic acid + sodium nitrite) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(ivacaftor + lumacaftor) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(ivacaftor + tezacaftor + bamocaftor potassium) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(ivacaftor + tezacaftor) + ivacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
4D-710 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABBV-191 - Drug Profile
Product Description
Mechanism Of Action
ABO-401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ACF-516 - Drug Profile
Product Description
Mechanism Of Action
ADDITIONAL SMALL MOLECULES 1 - Drug Profile
Product Description
Mechanism Of Action
AGL-503 - Drug Profile
Product Description
Mechanism Of Action
History of Events
alidornase alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANT-3273 - Drug Profile
Product Description
Mechanism Of Action
APPA-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARCT-032 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARO-ENaC2 - Drug Profile
Product Description
Mechanism Of Action
ARV-1907 - Drug Profile
Product Description
Mechanism Of Action
ascorbic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-010 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AvR-2V10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BBP-321 - Drug Profile
Product Description
Mechanism Of Action
BFP-002 - Drug Profile
Product Description
Mechanism Of Action
BFP-102 - Drug Profile
Product Description
Mechanism Of Action
BI-1323495 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-3720931 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIOC-51 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BOS-857 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BrB-102 - Drug Profile
Product Description
Mechanism Of Action
brensocatib - Drug Profile
Product Description
Mechanism Of Action
History of Events
brevenal - Drug Profile
Product Description
Mechanism Of Action
History of Events
BX-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Calcaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
CAT-5571 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CB-280 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CF-370 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CGT-001 - Drug Profile
Product Description
Mechanism Of Action
CHF-6333 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-101 - Drug Profile
Product Description
Mechanism Of Action
colistimethate sodium - Drug Profile
Product Description
Mechanism Of Action
CSA-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cysteamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
dirocaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
dornase alfa - Drug Profile
Product Description
Mechanism Of Action
Drug for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Drug to Inhibit SLPI for Asthma and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Drugs for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Drugs to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Drugs to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
EBX-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ECP-104 - Drug Profile
Product Description
Mechanism Of Action
EG-i08 - Drug Profile
Product Description
Mechanism Of Action
ELX-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ensifentrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
ETD-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ETD-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ETX-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EVXB-2 - Drug Profile
Product Description
Mechanism Of Action
fenretinide - Drug Profile
Product Description
Mechanism Of Action
History of Events
FTX-003 - Drug Profile
Product Description
Mechanism Of Action
fusidic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
galicaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Cystic Fibrosis and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
heparin sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
HY-006 - Drug Profile
Product Description
Mechanism Of Action
ICL4 Additional Candidates - Drug Profile
Product Description
Mechanism Of Action
ivacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
KB-407 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KIT-2014 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
LMS-611 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lonodelestat - Drug Profile
Product Description
Mechanism Of Action
History of Events
MG-277 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRT-5005 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
murepavadin - Drug Profile
Product Description
Mechanism Of Action
History of Events
N-115 - Drug Profile
Product Description
Mechanism Of Action
History of Events
nadolol - Drug Profile
Product Description
Mechanism Of Action
History of Events
nafamostat mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
NAS-415 - Drug Profile
Product Description
Mechanism Of Action
History of Events
navocaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
NBD1 Additional Candidates - Drug Profile
Product Description
Mechanism Of Action
nesolicaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
niclosamide - Drug Profile
Product Description
Mechanism Of Action
History of Events
NU-8 - Drug Profile
Product Description
Mechanism Of Action
OligoG - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotide to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oligonucleotides to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Optate - Drug Profile
Product Description
Mechanism Of Action
ORP-100S - Drug Profile
Product Description
Mechanism Of Action
History of Events
ORP-110 - Drug Profile
Product Description
Mechanism Of Action
OTP-602 - Drug Profile
Product Description
Mechanism Of Action
P-2114 - Drug Profile
Product Description
Mechanism Of Action
P-2176 - Drug Profile
Product Description
Mechanism Of Action
Pemziviptadil - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLG-0301 - Drug Profile
Product Description
Mechanism Of Action
posenacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
pravibismane - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection - Drug Profile
Product Description
Mechanism Of Action
History of Events
PTINC-733 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBR-042 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Enzyme to Inhibit DNA for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
renzapride - Drug Profile
Product Description
Mechanism Of Action
History of Events
RP-557 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RSBT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RTX-0001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RVT-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
S-1226 - Drug Profile
Product Description
Mechanism Of Action
History of Events
S-1229 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Sanguinate - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBI-001 - Drug Profile
Product Description
Mechanism Of Action
SCB-203 - Drug Profile
Product Description
Mechanism Of Action
seliciclib - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHP-111 - Drug Profile
Product Description
Mechanism Of Action
SHP-636 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SION-109 - Drug Profile
Product Description
Mechanism Of Action
SION-638 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Diabetic Foot Ulcers and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Respiratory Diseases - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Block SCNN1 for Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Penicillin Binding Protein for Gram-Negative Bacterial Infections and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
SNSP-113 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sodium calcium edetate + tobramycin - Drug Profile
Product Description
Mechanism Of Action
sodium nitrite - Drug Profile
Product Description
Mechanism Of Action
History of Events
SOL-512 - Drug Profile
Product Description
Mechanism Of Action
SPIRO-2101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPIRO-2102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPIRO-2110 - Drug Profile
Product Description
Mechanism Of Action
SPL-16 - Drug Profile
Product Description
Mechanism Of Action
SPL-232 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPL-24N - Drug Profile
Product Description
Mechanism Of Action
SPL-5A - Drug Profile
Product Description
Mechanism Of Action
SPL-5B - Drug Profile
Product Description
Mechanism Of Action
History of Events
SPL-8423 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SRI-41315 - Drug Profile
Product Description
Mechanism Of Action
SYD-0073 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYGN-303 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TA-270 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAVT-135 - Drug Profile
Product Description
Mechanism Of Action
teicoplanin - Drug Profile
Product Description
Mechanism Of Action
History of Events
thymalfasin - Drug Profile
Product Description
Mechanism Of Action
thymalfasin - Drug Profile
Product Description
Mechanism Of Action
TMD1 Candidates - Drug Profile
Product Description
Mechanism Of Action
tobramycin - Drug Profile
Product Description
Mechanism Of Action
tobramycin - Drug Profile
Product Description
Mechanism Of Action
History of Events
tobramycin + triclosan - Drug Profile
Product Description
Mechanism Of Action
History of Events
trimethylangelicin - Drug Profile
Product Description
Mechanism Of Action
History of Events
VS-009 - Drug Profile
Product Description
Mechanism Of Action
VX-121 + deutivacaftor + tezacaftor - Drug Profile
Product Description
Mechanism Of Action
History of Events
VX-551 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VXc-0522 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VXc-522 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XF-70 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YPT-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
zelpultide alfa - Drug Profile
Product Description
Mechanism Of Action
Cystic Fibrosis - Dormant Projects
Cystic Fibrosis - Discontinued Products
Cystic Fibrosis - Product Development Milestones
Featured News & Press Releases
Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
Jul 07, 2022: Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for public reimbursement of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children With cystic fibrosis ages 6 and older
Jun 11, 2022: Vertex to present data demonstrating significant benefits of long-term and early treatment With CFTR modulators at the European Cystic Fibrosis Conference
May 18, 2022: Recode therapeutics presents new preclinical data from mRNA-based program for cystic fibrosis at the ATS 2022 International Conference
Apr 21, 2022: Health Canada approves Vertex’s Trikafta for cystic fibrosis in children
Apr 18, 2022: ContraFect announces multiple presentations of new data demonstrating the potential of its Direct Lytic Agent CF-370 to address antimicrobial resistance at the 32nd Annual ECCMID Meeting
Apr 12, 2022: Entrinsic Bioscience steps closer to amino acid formulation as therapy for cystic fibrosis
Apr 11, 2022: Nabriva Therapeutics announces first patient enrolled in phase 1 trial of XENLETA (lefamulin) in adult patients with cystic fibrosis
Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
Mar 29, 2022: Eloxx Pharmaceuticals announces therapeutic development Award from Cystic Fibrosis Foundation
Mar 26, 2022: Vertex announces reimbursement agreement in Australia for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients With cystic fibrosis ages 12 years and older with at least one F508del mutation in the CFTR gene
Mar 25, 2022: Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H Mutation in the CFTR Gene
Jan 12, 2022: EC approves Vertex’s combination therapy for cystic fibrosis in children
Jan 05, 2022: SpliSense announces FDA and EMA grant Orphan Drug Designation to SPL84-23-1 for the treatment of cystic fibrosis
Jan 05, 2022: Peptilogics receives award from the Cystic Fibrosis Foundation to investigate PLG0301 as potential dual-acting treatments for lung infections associated with cystic fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cystic Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cystic Fibrosis - Dormant Projects, 2022
Cystic Fibrosis - Discontinued Products, 2022
Cystic Fibrosis - Discontinued Products, 2022 (Contd..1)

LIST OF FIGURES

Number of Products under Development for Cystic Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications